Men whose prostate cancer comes back after surgery and get radiation therapy when their PSA is still very low (under 50 ng/L) live longer and are less likely to get cancer spread than those who wait until their PSA is much higher.

40

Pro

0

Against

Evidence from Studies

Supporting (1)

40

Community contributions welcome

40

Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review

Systematic Review

Human

2024 Apr 8

The study found that starting treatment when PSA is very, very low leads to better survival, which matches the idea that starting treatment earlier (at lower PSA) is better — even if it didn’t test exactly 50 vs. 500.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review

Score: 40

DOI: 10.3390/biomedicines12040822

Similar Assertions

After prostate cancer comes back, how high the PSA is when you start radiation therapy matters more for your survival than how aggressive the cancer looked when it was first diagnosed.

40

0

83%

If radiation therapy brings the PSA level back to undetectable after cancer comes back, the patient is much more likely to live longer—even if the PSA was already high when treatment started.

40

0

76%